华兰疫苗(301207) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 reached ¥144,762,101.26, a significant increase of 892.96% compared to ¥14,578,885.25 in the same period last year[7] - Net profit attributable to shareholders was ¥93,967,811.66, marking an increase of 11,156.09% from a loss of ¥849,919.03 in the previous year[7] - Basic earnings per share rose to ¥0.2349, compared to a loss of ¥0.0023 per share in the same quarter last year, reflecting a growth of 10,313.04%[7] - Operating profit for the quarter was 105,903,077.92, compared to an operating loss of 7,161,665.06 in Q1 2022[35] - Total profit for the quarter reached 105,961,150.80, a turnaround from a total loss of 7,297,154.69 in the previous year[35] Cash Flow - The net cash flow from operating activities was ¥192,546,198.76, a 472.36% increase from a negative cash flow of ¥51,709,044.15 in Q1 2022[20] - Cash inflow from investment activities totaled ¥1,134,548,139.19, up from ¥398,011,360.96 in the prior period, marking an increase of approximately 185.5%[43] - The company recorded a cash outflow from financing activities of 1,500,000.01, compared to an outflow of 3,837,499.99 in the previous year[37] Assets and Liabilities - The total assets at the end of the reporting period were ¥7,102,287,203.11, a slight increase of 0.38% from ¥7,075,517,368.83 at the end of the previous year[7] - Total current assets decreased to ¥4,063,364,164.46 from ¥4,192,738,083.14, a decline of about 3.1%[26] - Total liabilities decreased to 1,504,541,278.82 from 1,578,941,039.38 year-over-year[32] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period is 16,683[22] - The top shareholder, Hualan Biological Engineering Co., Ltd., holds 67.50% of shares, totaling 270,000,000 shares[22] - The company has a total of 364,002,650 restricted shares, with 58,001,975 shares released during the period[29] Inventory and Expenses - The company reported a significant increase in inventory, which rose by 92.25% to ¥321,355,281.16, primarily due to an increase in work-in-progress[10] - The company experienced a 3927.65% increase in selling expenses, totaling ¥43,659,973.15, due to higher service fees associated with increased vaccine sales[16] - Total operating costs amounted to ¥90,312,538.22, compared to ¥39,965,718.51 in the prior period, indicating an increase of about 126.5%[41] Investment and Income - The company’s investment income increased by 286.61% to ¥16,723,286.29, attributed to higher returns from financial investments[16] - The total non-recurring gains and losses amounted to ¥25,934,688.48 after tax, indicating a strong performance in non-operational areas[14] - The company achieved other income of ¥4,397,479.86, compared to ¥1,094,230.65 in the previous period, representing an increase of approximately 301.5%[41] Research and Development - Research and development expenses for the current period were ¥28,994,998.34, down from ¥35,308,146.72 in the previous period, indicating a decrease of about 17.9%[41] Future Outlook - The company plans to continue expanding its market presence and developing new products and technologies[30]